Kristen M. Thomas, MD
Pathology Resident, New York University Medical School, New York, New York

Amy V. Rapkiewicz, MD
Assistant Professor of Pathology
Director, Autopsy Service
Director, Pathology Course NYUSOM, NYUMC/Bellevue Hospital, New York, New York

David E. Kleiner, MD, PhD
Director, Autopsy Service, National Cancer Institute, Betheseda, Maryland

Upon completion of this activity, you will be able to:

• define the pathophysiologic mechanisms of pulmonary capillary hemangiomatosis.
• recognize the clinical and radiologic manifestations of pulmonary capillary hemangiomatosis that may help facilitate antemortem diagnosis.
• recognize the primary gross and microscopic findings responsible for the signs and symptoms of pulmonary capillary hemangiomatosis.
• differentiate between pulmonary capillary hemangiomatosis and pulmonary veno-occlusive disease.
• discuss the effects of the overexpression of platelet-derived growth factor (PDGF)-B and PDGFR-® in patients with pulmonary capillary hemangiomatosis.
• discuss current treatment options for patients with pulmonary capillary hemangiomatosis, including the adverse effects of prostacyclin therapy.